cyrilzakka/clinical-trials huggingface dataset:
The Effects of Premeal Consumption of Protein-enriched Bar on Blood Glucose Level and Secretion of Hormones

The aim of this study is to explore premeal protein-enriched bar effect in postprandial glucose levels and concentration of plasma incretin hormones \[glucagon-like peptide 1 (GLP-1) and/or glucose-dependent insulinotropic polypeptide (GIP)\] in healthy subjects and those with type 2 diabetes.

Fifteen healthy subjects and fifteen subjects with type 2 diabetes treated by diet and/or metformin, SU, DPP4 inhibitors will be recruited. Every subject will studied on 2 separate days in random order with 1-2 week intervals. These participants will consume protein enriched bar followed by a standardized high-glycemic-index breakfast in a hospital setting or breakfast followed protein enriched bar in a cross-over fashion. Blood sampling will be done at the moment of start of breakfast (0 min) and then 10, 20, 30, 60, 90, 120, 150, 180 min. Plasma glucose levels, total/active GLP-1, GIP, insulin, C-peptide, glucagon will be measured. Incremental area under the curve (iAUC) of glucose level and hormone from 0 min to 180 min will be calculated.

Eligibility Criteria:
Inclusion Criteria:

* BMI 18.5\~35 kg/m2
* Healthy volunteer:

  * never diagnosed by diabetes and
  * fasting plasma glucose \<=100mg/dl and HbA1c \<6.0%
* participants with diabetes

  * diagnosed by diabetes
  * if treated by diet, HbA1c 6.0\~9.0%
  * if treated by metformin or SU, HbA1c 6.0\~10.0%
  * if treated by DPP4 inhibitor HbA1c 6.0\~9.0%

Exclusion Criteria:

* Those who diagnosed by Type 1 diabetes
* History of DKA
* History of insulin therapy
* Allergy to wheat, flour, nuts, milk
* Pregnancy/lactation
* AST or ALT \>2.5 times of upper normal reference range
* eGFR \<30 mL/min/1.73m2
* Hb \<10g/dl
* History of GI surgery (except hemorrhoidectomy, appendectomy)
Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors

The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experiences by patients that receive AZD4877 on a weekly basis


Eligibility Criteria:
Inclusion Criteria:

* Advanced solid tumors for which standard treatment doesn't exist or is no longer effective.
* Relatively good overall health other than your cancer.

Exclusion Criteria:

* Poor bone marrow function (not producing enough blood cells).
* Serious heart conditions.
* Poor liver or kidney function.
Retrospective Examination of Electroencephalography Signals of Individuals With Different Eating Disorders

The aim of this study was to investigate the difference between electroencephalography (EEG) data and current psychological status of individuals diagnosed with anorexia nervosa (AN) and bulimia nervosa (BN).

The data used in this study were obtained from individuals aged 18 and younger with eating disorders who applied to Üsküdar University NP Istanbul Brain Hospital. Two different diagnostic groups, Anorexia Nervosa and Bulimia Nervosa, were included in the study. Demographic information, secondary diagnosis status, Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Eating Attitude Test - 40 (EAT-40) scores and EEG data were used to investigate the differences between eating disorders. Comparison of neurological differences between individuals with AN and BN was done retrospectively.

This information, which will be obtained for AN and BN, which are diseases in which severe deterioration in behavior and perception are seen, can give advice to experts in planning treatment and rehabilitation processes.

Eligibility Criteria:
Inclusion Criteria:

* Being diagnosed with anorexia nervosa or bulimia nervosa to the DSM-V diagnostic criteria
* 18 years and younger
* Having an EEG data

Exclusion Criteria:

* Having an EEG data taken in a center other than NP Istanbul Brain Hospital
* Lack of "Beck Depression Inventory", "Beck Anxiety Inventory" and "Eating Attitude Test-40" scale values in the patient file
Use of CXCL9 as a Biomarker of Acthar Efficacy

The objective is this study is to test whether use of Acthar gel in the context of sarcoidosis will lead to improved symptoms and lung function and correlate with decreased levels of predictive blood biomarkers, like chemokine ligand 9 (CXCL9).

The investigators will test whether Acthar gel's anti-inflammatory properties will modulate immune cells and lead to decreases in blood biomarkers and improvements in clinical parameters. Specific Aim 1 will examine the levels of the predictive biomarker, chemokine ligand 9 (CXCL9), and related transcripts, and determine whether they decrease in participants over time while taking Acthar. Specific Aim 2 will test whether the biologic changes measured in blood correlate to clinical markers, including lung function and symptom scores. Since the investigators have found that CXCL9 predicts clinical course, they hypothesize that CXCL9 transcript levels in the blood will decrease over time in pulmonary sarcoidosis participants whose clinical outcome measures improve with Acthar.

Eligibility Criteria:
Inclusion Criteria:

* Biopsy-proven diagnosis of sarcoidosis with demonstrated pulmonary involvement
* Refractoriness to or intolerance of immunosuppressive agents like prednisone or methotrexate

Exclusion Criteria:

* Smoking
* Cancer
* Chronic infections (e.g. tuberculosis, viral, fungal, bacterial)
* Inflammatory conditions
* Coexisting lung disease
* Congestive heart failure
* Uncontrolled hypertension
* Recent surgery
* Active peptic ulcers
* Osteoporosis
Comparison of Five-year Survival and Disease-free Survival in Patients Diagnosed With Endometrium Cancer Who Underwent Total Laparoscopic Hysterectomy With and Without Uterine Manipulator

Comparison of five-year survival and disease-free survival in patients diagnosed with endometrium cancer who underwent total laparoscopic hysterectomy with and without a uterine manipulator


Eligibility Criteria:
Inclusion Criteria:

* patients suitable for laparoscopic surgery patients ages 18-75 patients diagnosed figo stage 1 and 2 endometrial cancer

Exclusion Criteria:

* patients not suitable for laparoscopic surgery patients diagnosed figo stage 3 and 4 endometrial cancer pregnant patients
Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies

To evaluate the effects of patupilone on the pharmacokinetics of warfarin in patients with advanced malignancies.


Eligibility Criteria:
Inclusion criteria

* Age ≥ 18 years of age
* Life expectancy ≥3 months
* Histologically documented advanced solid tumors which have progressed after standard systemic therapy or for which standard systemic therapy does not exist
* Agents containing warfarin or heparin must be discontinued 7 days prior to enrollment in the study

Exclusion criteria

* History of/or active bleeding disorders
* Known hypersensitivity to warfarin or related compounds
* The use of vitamin K
* Central lines that require anticoagulant maintenance
* The use of agents containing warfarin and heparin
* Known diagnosis of human immunodeficiency virus (HIV) infection, hepatitis Other protocol-defined inclusion/exclusion criteria may apply
Evaluation of Posterior Component Separation Technique in the Management of Complex Ventral Hernia.

* Assess short term outcome of posterior component separation technique(PCS) including the regain of the physiological function of the abdominal wall.
* Detect most common post operative complications related to AWR techniques in a 6 months duration after operation.

posterior component separation(PCS) is one of the surgical techniques used in abdominal wall reconstruction plan foe management of relatively complex ventral hernia ,which cannot be treated with the conventional surgical way.

With or without transverses abdominis release(TAR) technique, (PCS) became widely accepted as surgical technique specially for large sized hernia defect, previous multiple laparotomies or unhealth abdominal soft tissue.

This study has a primary outcome which is detection of recurrence rate in patients under went posterior component separation technique in a period of 6 month after operation.

Eligibility Criteria:
Inclusion Criteria:

* patients with complex ventral hernia with contraindication to the conventional surgical therapy.

Exclusion Criteria:

1. patients with contraindication to long standing anesthesia.
2. patients with emergency hernia situation.
3. pregnant patients.
Safety Study of Human Anti-Cytomegalovirus Monoclonal Antibody

The purpose of this study is to compare the safety profile in healthy adult volunteers of single or multiple intravenous administrations of TCN-202 as compared with placebo.

Human cytomegalovirus (HCMV) disease remains an unmet medical need: In the US, the estimated prevalence of congenital HCMV infection is \~1% and is one of the leading causes of permanent hearing loss and neurological deficits in children. In immunocompromised individuals such as transplant recipients it can cause serious life-threatening disease and may significantly increase the risk of graft rejection. As existing therapies for HCMV can have serious side effects, there remains a medical need for safe and effective treatment of HCMV disease.

Eligibility Criteria:
Inclusion Criteria:

* Healthy adult volunteers
* Normal lab tests

Exclusion Criteria:

* Prior treatment with monoclonal antibody
Clinical and Economic Consequences of Left Atrial Bipolar Radiofrequency Ablation of Persistent and Permanent Atrial Fibrillation During Cardiac Surgery

The clinical effects of intra-operative radiofrequency ablation in patients with persistent or permanent atrial fibrillation and an indication for an implantation of a heart valve prosthesis or coronary bypass surgery are the purposes of this study. The study will examine if and to what extent the quality of life and the use of medical care differs between patients with and without ablation. Furthermore, there will be thorough echocardiographic examinations of the heart to detect differences between the different treatment groups. The patients will be followed for one year after treatment.


Eligibility Criteria:
Inclusion Criteria:

* Persistent atrial fibrillation
* Permanent atrial fibrillation
* Mitral valve defect
* Tricuspid valve defect
* Aortic valve defect
* Coronary artery disease

Exclusion Criteria:

* Pregnancy
* Age \< 18 or \> 75 Years
* Emergency surgery
* Left dominant coronary circulation (relative contraindication)
* Coronary arteries of the posterior wall without pathological findings: No inclusion
* Stenosis of the posterior wall vessels, supplied with a CABG (coronary artery bypass grafting): Inclusion possible
* Left ventricular ejection fraction \< 30%
* Size of the left atrium \> 7 cm
* Thrombosis of the left atrial appendage
* Leads in the coronary sinus
* Atrial flutter
* Infective endocarditis
* Reoperation
* Participation in other studies
* Life expectancy of less than 12 months
* Psychiatric disorders
* Hyperthyreosis
Discomfort Evaluation During Atraumatic Restorative Treatment in Children

This study evaluates the patient 's discomfort when submitted to partial caries removal through the atraumatic restorative treatment compared to chemo-mechanical caries removal using Papacarie™ gel.

This study will evaluate the patient 's discomfort through oximeter (measuring the heart rate of the caries) prior to removal of the carious tissue, and when subjected to partial caries removal through the atraumatic restorative treatment compared to removal of chemo - mechanical caries with Papacarie gel ™.

Eligibility Criteria:
Inclusion Criteria:

* normoreactive,
* in good general health conditions,
* cooperative during screening,
* with at least one oclusal caries cavity in primary molars.
* Caregivers and/or children's parents must accept and sign the consent form.
* Children must accept their participation by nodding (assent).

Exclusion Criteria:

* pulp exposition,
* spontaneous pain,
* mobility,
* fistula,
* swollen area around the tooth,
* furcation,
* cervical lesion,
* restorations,
* sealants,
* developmental defect of enamel.
Transanal Versus Laparoscopic Total Mesorectal Excision for Rectal Cancer

This study is designed to evaluate the short-term and long-term results after transanal total mesorectal excision (TaTME) for the resection of mid and low rectal cancer compared with laparoscopic total mesorectal excision（LaTME）.

Colorectal cancer (CRC) including rectal cancer is one of the most common gastrointestinal tumors, and its incidence is third in the world. At present，surgical treatments is the main means to cure CRC. Total mesorectal excision (TME) is the gold standard for rectal cancer surgery. Transanal total mesorectal excision (TaTME) was recently developed to overcome technical difficulties associated with LaTME and open TME. Most reports are retrospective studies. More studies, especially large-scale, randomized controlled trials are needed to establish the best indications for TaTME for mid and low rectal cancer.This is a single-center, open-label, non-inferiority, randomized controlled trial. A total of 120 eligible patients will be randomly assigned to TaTME group and LaTME group at a 1:1 ratio. It will provide valuable clinical evidence for the objective assessment of the oncological safety，efficacy and potential benefits of TaTME compared with LaTME for mid and low rectal cancer.

Eligibility Criteria:
Inclusion Criteria:

* 18 years \< age \< 80 years
* Body mass index (BMI) \<30 kg/m2
* Tumor located in mid and low rectum ( the lower border of the tumor is located distal to the peritoneal reflection)
* Pathological rectal carcinoma
* Clinically diagnosed cT1-3N0-2 M0 lesions according to the 7th Edition of AJCC Cancer Staging Manual with or without neoadjuvant therapeutic history
* Tumor size of 5 cm or less
* ECOG score is 0-1
* ASA score is Ⅰ-Ⅲ
* Informed consent

Exclusion Criteria:

* Requiring a Mile's procedure
* Fecal incontinence
* History of inflammatory bowel disease
* Pregnant woman or lactating woman
* Severe mental disease
* Intolerance of surgery for severe comorbidities
* Previous abdominal surgery
* Emergency operation due to complication (bleeding, perforation or obstruction) caused by rectal cancer
* Requirement of simultaneous surgery for other disease
Effect of a Botanical Ingredient in Healthy Subjects With Anxiety and Poor Sleep Quality

Randomized, controlled, double-blind, single-center clinical trial with two parallel arms depending on the product consumed (experimental product and placebo product) to analyze the efficacy of a botanical extract in reducing anxiety and improving sleep quality.

Subjects who meet the selection criteria will be randomly assigned to each of the study groups (investigational product dose or placebo, depending on the group to which they have been assigned).

The product to be consumed is a botanical extract. Participants will consume the product for 90 days. They should consume one capsule one hour before going to sleep.

They will make a total of five visits to the research laboratory and the tests preestablished in the protocol will be performed. Subsequently, a statistical analysis will be performed with the variables measured in the study to obtain the results.

Eligibility Criteria:
Inclusion Criteria:

* Healthy adults.
* Moderate levels of anxiety by STAI.
* Low sleep quality by PSQI.
* Volunteers able to understand the clinical study and willing to comply with its procedures and requirements.

Exclusion Criteria:

* Serious or terminal illness.
* Subjects with body mass index above 32 kg/m2. Pregnant or lactating women.
* Participation in another study involving blood draws or dietary intervention.
* Organic dementias such as Alzheimer's, Huntington's disease, Parkinson's and senile dementia.
* Hypersensitivity to the components of the formula.
* Use of medications that alter cognitive functions or sleep, such as barbiturates, anticonvulsants, benzodiazepines, antidepressants, neuroleptics, alcohol and illicit drugs.
* Subjects with known allergy to some of the study components.
* Inability to understand the informed consent.
Time Restricted Eating and Innate Immunity

The goal of this cross over study is to investigate the effect of short term time restricted eating (TRE) on the innate immune system in patients with a history of myocardial infarction.

In the recent years, research has shown the prominent role of low grade systemic inflammation in cardiovascular disease (CVD) and the crucial role myeloid cells, mainly monocytes and macrophages, play in atherogenesis. Time restricted eating (TRE), i.e. eating the normal amount of calories within a limited time period per day, has a beneficial effect on multiple factors involved in the development of CVD, such as blood pressure, heart rate, lipid and blood glucose levels, and insulin sensitivity. TRE also reduces markers of systemic inflammation and reduces the number of circulating monocytes.

It is now hypothesized that TRE reduces the pro-inflammatory monocyte phenotype of patients with a history of myocardial infarction. Therefore, the investigators will perform a exploratory prospective randomised open label blinded endpoint cross-over study to investigate the effect of short term TRE on the innate immune system in patients with a history of myocardial infarction.

Eligibility Criteria:
Inclusion Criteria:

* Adult (age \>18 years)
* Diagnosed with a myocardial infarction (between 1 and 5 years ago)
* Body mass index between 20 and 35 kg/m2
* Able to understand, be motivated and follow the study related procedures
* Able to understand and give written informed consent

Exclusion Criteria:

* Myocardial infarction (defined as an increase in cardiac enzymes in combination with symptoms of ischemia or newly developed ischemic ECG changes), coronary artery bypass graft surgery or other major (cardiovascular) surgery, stroke or transient ischemic attack (TIA) in the past 1 year prior to screening.
* Use of immunomodulatory drugs
* Use of drugs that need to be taken with food.
* Diabetes Mellitus type I and type II
* Medical history of any disease associated with immune deficiency (either congenital or acquired, including chemotherapy, active malignancy, organ transplant) or auto immune disease
* Clinically significant infections within 1 months prior to start of or during intervention period or control period (defined as fever \>38.5).
* Vaccination \<1 month before start of or during intervention or control period.
* Eating disorders
Digital Rectal Exam Proficiency Tool

A digital rectal exam proficiency tool, titled the 'DiRECT' was developed based on the consensus of 10 experts. The purpose of this study is to validate this tool for use in both undergraduate and graduate medical education .

First, it will be validated on 120 anesthetized patients undergoing prostate surgery, comparing responses on the digital rectal exam clinical tool (DiRECT) from both expert and novice clinicians, with surgical pathology reports. The second phase of validation will involve the participation of standardized patients, medical students and MUTA (medical urology teaching associate). During a standardized patient exercise focusing on digital rectal exam in the University of Virginia School of Medicine curriculum, 160 second-year medical students will be given the DiRECT to document their examination. An attending physician will also attend the standardized patient exercise and document their examination for comparison with the medical students.

The third phase includes 8 residents and up to10 attendings in the Urology clinic, who will independently complete the DiRECT documenting their DRE in the course of usual care.

Comparison of faculty and student/trainee responses in all phases will be used for validation of the clinical tool for further use in medical education.

Eligibility Criteria:
Inclusion Criteria:

Subjects who are patients:

* Patients who are male and adults ≥ 30 years of age
* Standardized patients between the ages of 30-80 years participating in the University of Virginia School of Medicine activity for second-year students learning digital rectal exams

Subjects who are clinicians:

• Attending physician, resident physician, or medical student scrubbed in for a prostatectomy or cystectomy, seeing patients in urology clinic, or participating in the School of Medicine activity for second year students learning digital rectal exams

Exclusion Criteria:

List the criteria for exclusion

* Patients who do not have a prostate
* Patients with previous pelvic/perineal surgery
* Previously enrolled in this study
Intelligence Changes Following Minor Surgery

Animal studies showed that many general anesthetics might result in neuron apoptosis and neurocognitive impairment in the developing brain. However results from human studies are conflicted. In present study, the investigators examined the association between early exposure to anesthesia and surgery for minor surgery and intelligence changes in adolescence using the Wechsler Intelligence Scale for Children.


Eligibility Criteria:
Inclusion Criteria:

1. Born from 1995
2. Male
3. Parents or guardian agree to attend this study
4. Undergone minor surgery (Repair of hypospadias, phimosiectomy, cryptorchidectomy or cryptorchidopexy and repair of inguinal hernia)
5. Children who scarify the No.1 to No.3 but no experience of any surgery.
6. Those who undergone minor surgery in Renji Hospital 4-6years ago.

Exclusion Criteria:

1. Any congenital central nervous system diseases
2. Any congenital heart diseases
3. Any congenital dysgnosia
4. Birth weight less than 2kg
5. Ever been hypoxic encephalopathy when birth